Cayman ARQ 092

ARQ 092 is an allosteric, orally bioavailable, pan-Akt inhibitor (IC₅₀s = 5.0, 4.5, and 16 nM for Akt1, Akt2, and Akt3, respectively). It is selective for Akt isoforms over a panel of 303 other kinases. ARQ 092 binds inactive Akt and prevents membrane localization and full Akt activation.^, It also directly inhibits the membrane-associated active form of Akt, preventing phosphorylation of downstream targets.^, ARQ 092 inhibits the proliferation of a wide range of cancer cells in vitro, inhibits the mutated Akt form found in Proteus syndrome, and attenuates heterotypic cell-cell interactions in a mouse model of sickle cell disease.^,,,

WARNING This product is not for human or veterinary use.